​昆嵛讲坛第二十二讲 | 普渡大学药物研发院院长张仲寅教授作“Advancing drug discovery by targeting protein tyrosine phosphatases”学术报告

2024-07-23 19:12

2024年7月19日，新药创制省实验室举办昆嵛讲坛第二十二讲，普渡大学药物化学与分子药理学系Robert C. and Charlotte P. Anderson系主任、化学基因组研究中心主任、药物研发院院长张仲寅教授作题为“Advancing drug discovery by targeting protein tyrosine phosphatases”的学术报告，报告由新药创制省实验室常务副主任、代谢与神经疾病药物研究中心主任李佳研究员主持。省实验室科研人员、研究生等100余人参会。

报告会上，张仲寅教授以“Advancing drug discovery by targeting protein tyrosine phosphatases”，通过靶向蛋白酪氨酸磷酸酶推进药物发现为主题，从蛋白酪氨酸磷酸酶（PTP）的组成、主要功能及其抑制剂发现的三个不同视角进行了深入分析和精彩报告。

张仲寅教授指出蛋白质酪氨酸磷酸化改变的异常细胞信号是导致人类疾病的主要因素。缺陷蛋白酪氨酸磷酸化驱动的异常细胞事件为靶向干预提供了巨大的机会。鉴于蛋白质酪氨酸磷酸化的可逆性，在蛋白质酪氨酸磷酸酶（PTP）水平上操纵疾病生物学具有巨大的潜力。张仲寅教授描述了他们团队最近在致癌PTP方面的工作，这些工作为其在肿瘤发生中的作用提供了新的见解。张仲寅教授还介绍了团队发现的具有有效体内活性的高效选择性PTP抑制剂，其有助于对复杂信号转导通路中的PTP进行功能分析，并可能成为治疗多种人类疾病的新疗法。

 张仲寅教授全新的科研理念赢得现场师生的好评。报告交流环节，李佳研究员及多名老师和同学针对张仲寅教授讲座的内容提出问题，并结合自己的研究方向和课题与张仲寅教授展开学术讨论。会前，张仲寅教授还参观了公共仪器平台及实验室。

张仲寅教授学术渊博，报告内容生动详实结合实践，涉及生物学，生物化学等等多领域的前沿信息，为老师和同学今后的研究和学习给予极大启发。

李佳研究员主持报告会

张仲寅教授作报告

与会人员参加学术报告

附张仲寅教授简介:

Zhong-Yin Zhang graduated from Nankai University in 1984 with a B.S. in Chemistry.  He pursued his Ph.D. in Chemistry from Purdue University under the tutelage of Dr. Robert Van Etten, where he carried out the first mechanistic study on a protein tyrosine phosphatase (PTP) and graduated in 1990.  After a brief stint at Upjohn Co, he completed his postdoctoral training at the University of Michigan from 1991-1994, where he continued his work on the PTPs in the laboratory of Dr. Jack Dixon. Zhong-Yin established his own laboratory in 1994 at Albert Einstein College of Medicine, where he rose to the rank of Professor in 2002. From 2005-2015, Zhang was Robert A. Harris Professor and Chairman of the Department of Biochemistry and Molecular Biology at Indiana University School of Medicine. In 2016, Zhang moved back to Purdue as Distinguished Professor of Medicinal Chemistry, Robert C. and Charlotte P. Anderson Chair in Pharmacology, and Head of the Department of Medicinal Chemistry and Molecular Pharmacology. He also serves as the Director of the Institute for Drug Discovery at Purdue University. 

His research spans the disciplines of chemistry and biology with an emphasis on the structure and function of protein tyrosine phosphatases (PTPs) and development of PTP inhibitors as novel therapeutics. His group performed experiments that defined the catalytic mechanism, rate-limiting step, and transition state of the PTP-catalyzed reaction; illuminated the molecular basis for PTP substrate recognition; and elucidated the biochemical mechanisms of several PTP-mediated cellular signaling pathways. In addition, he pioneered a novel paradigm for the acquisition of potent and selective PTP inhibitors by targeting both the PTP active site and unique pockets in the vicinity of the active site. These efforts have produced many of the most potent and selective PTP inhibitors and degraders available today with excellent in vivo efficacy in animal models of oncology and other diseases. He has authored 311 publications (H-index 96; i10 index 261; 27,995 citations – Google Scholar, July 2024), 20 issued patents, co-founded and consulted for several pharmaceutical companies. He is an internationally recognized authority in the field of PTPs. He is the recipient of a Sinsheimer Scholar, an Irma T. Hirschl Career Scientist and an elected Fellow of the American Association for the Advancement of Science.